CSF Biomarker May Support Lewy Body Diagnosis - Quiz - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

CSF Biomarker May Support Lewy Body Diagnosis

A multicohort analysis suggests cerebrospinal fluid DOPA decarboxylase may help distinguish dementia with Lewy bodies and Parkinson’s disease from Alzheimer’s disease and controls

  • By

  • Henry Thomas

  • April 3, 2026

  • 2 min

Share

Original Source(s)

CSF Biomarker May Support Lewy Body Diagnosis

  • by Henry Thomas

  • April 3, 2026

Related Content

Top 10 Evidence-Based Essentials in Neurology

A structured framework of guidelines, trials, therapies, and tools used in clinical practice.

Could Digital Twins Forecast Forensic Risk?

Researchers outline a proposed three-level framework spanning patient monitoring, ward operations, and forensic system planning.

When Bad Data Enters the Drug Pipeline

Federal prosecutors allege that a Florida physician and research staff fabricated clinical trial records that were submitted into database systems used to evaluate investigational drugs.